Table 3. Summary of the clinical trials on third-generation EGFR-TKIs combined with SBRT.

Clinical trial	Setting	Cases	Condition	Treatment	Measures	Study completion
NCT04908956	Phase II	60	Oligo-metastatic EGFR-mutant NSCLC	Risk-adapted SBRT × up to 5 fractions, osimertinib 80 mg once daily	Pneumonia grade ≥2, PFS, RECIST v. 1.1	2023/3/26
NCT05167851	Phase II	68	Oligometastatic EGFR-mutant NSCLC	Lazertinib 240 mg once daily oral (PO); SBRT to oligometastatic sites	PFS, OS, distant PFS, ORR, DOR, CTCAE	2023/12/25
NCT04764214	Phase II	56	Oligometastatic EGFR-mutant NSCLC	Osimertinib 80 mg once daily; consolidative SBRT to all residual disease	PFS, OS, CTCAE v. 5.0	2023/12/31
NCT05583409	Not applicable	72	EGFR-mutant NSCLC with fewer than 5 metastatic focus	Received SBRT after 3 months of osimertinib treatment; osimertinib 80 mg once daily	PFS, OS	2025/12/30

EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; SBRT, stereotactic radiation therapy; NSCLC, non-small cell lung cancer; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors; PO, per os; OS, overall survival; ORR, objective response rate; DOR, duration of response; CTCAE, Common Terminology Criteria for Adverse Events.